HealthDay - WEDNESDAY, Feb. 9 (HealthDay News) -- A pair of tumor-inhibiting drugs more than doubled the progression-free survival time for patients with a rare type of pancreatic cancer, according to two new studies.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.